GSK and Relation Therapeutics Collaborate on Fibrosis and Osteoarthritis Research with AI-Driven Approach
Collaboration:
Relation Therapeutics and GSK have entered into a collaboration to identify new targets for fibrotic diseases and osteoarthritis using AI and machine learning45.
Financial Terms:
GSK has provided $45 million upfront to Relation Therapeutics as part of the collaboration5.
Technology:
Relation Therapeutics uses single-cell multi-omics, functional assays, and machine learning to understand disease biology and develop transformational medicines1.
Focus:
The collaboration aims to leverage AI and machine learning to crack the biology of fibrosis and osteoarthritis, emphasizing the importance of biological understanding in drug discovery4.
Partnership Goals:
The partnership seeks to identify and develop new therapeutic targets for fibrotic diseases and osteoarthritis, leveraging Relation Therapeutics' AI-driven approach and GSK's pharmaceutical expertise45.
Sources:
4. https://endpts.com/its-the-biology-stupid-relation-and-gsk-team-up-on-fibrosis-osteoarthritis/
5. https://www.fiercebiotech.com/biotech/gsk-pens-45m-upfront-collab-ai-biotech-identify-fibrotic-osteoarthritis-targets